SCHEMBL6570592

SCHEMBL6570592

[CH2]c1ccc(C(C)(C)c2ccc3c(c2)C(C)(C)CCC3(C)C)cc1

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RXRA P19793 12/20 0.64
RXRB P28702 9/20 0.64
RARB P10826 8/20 0.38
RARG P13631 8/20 0.38
RXRG P48443 6/20 0.38
RARA P10276 6/20 0.38
CYP26A1 O43174 5/20 0.35
CYP3A4 P08684 3/20 0.35
MEN1 O00255 1/20 0.35
PGR P06401 1/20 0.35
ADORA3 P0DMS8 1/20 0.35
TBXA2R P21731 1/20 0.35
BLVRB P30043 1/20 0.35
KMT2A Q03164 1/20 0.35
CYP26B1 Q9NR63 3/20 0.34
CRABP2 P29373 1/20 0.34
ESR1 P03372 1/20 0.33
ESR2 Q92731 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2654848 0.83 RXRA (0.64) RXRARXRBRARBRARGRXRG
SCHEMBL4047286 0.78 RXRA (0.46) RXRARXRBRARBRARGRXRG
SCHEMBL6147245 0.75 RXRA (0.50) RXRARXRBRARBRARGRXRG
SCHEMBL6147714 0.72 RXRA (0.55) RXRARXRBRARBRARGRXRG
SCHEMBL8730978 0.72 RXRA (0.51) RXRARXRBRARBRARGRXRG
SCHEMBL14492781 0.71 RXRA (0.53) RXRARXRB
SCHEMBL1619225 0.71 RXRA (0.53) RXRARXRB
SCHEMBL6146095 0.71 RXRA (0.54) RXRARXRBRARBRARGRXRG
SCHEMBL10899364 0.71 RARB (0.63) RXRARXRBRARBRARGRXRG
SCHEMBL1619281 0.70 RXRA (0.52) RXRARXRBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1392326-A1 COMBINATION THERAPY COMPRISING GLUCOSE REABSORPTION INHIBITORS AND RETINOID-X RECEPTOR MODULATORS Ortho McNeil Pharmaceutical, Inc. (US) 2004-03-03 EP claimed
WO-2002080935-A1 COMBINATION THERAPY COMPRISING GLUCOSE REABSORPTION INHIBITORS AND RETINOID-X RECEPTOR MODULATORS ORTHO MCNEIL PHARMACEUTICAL, INC. (US) 2002-10-17 WO claimed
EP-1392326-A1 COMBINATION THERAPY COMPRISING GLUCOSE REABSORPTION INHIBITORS AND RETINOID-X RECEPTOR MODULATORS Ortho McNeil Pharmaceutical, Inc. (US) 2004-03-03 EP disclosed
WO-2002080935-A1 COMBINATION THERAPY COMPRISING GLUCOSE REABSORPTION INHIBITORS AND RETINOID-X RECEPTOR MODULATORS ORTHO MCNEIL PHARMACEUTICAL, INC. (US) 2002-10-17 WO disclosed